How to Reconstitute TB-500, Store It Safely, and Calculate Your Dose

What TB-500 Actually Is (and What It Is Not)

TB-500 is a synthetic, water-soluble peptide derived from the last 17 amino acids of thymosin beta-4, a protein encoded by the TMSB4X gene on the X chromosome. The full-length protein thymosin beta-4 promotes actin polymerization, angiogenesis, and wound healing in preclinical models. The commercial fragment sold as TB-500 specifically refers to the Ac-SDKP tetrapeptide region or, depending on supplier, a longer 43-amino-acid chain. The two are not identical, and labeling varies widely between compounding sources.

TB-500 is not FDA-approved for any human indication. The FDA removed thymosin beta-4 from the list of bulk substances that may be compounded under 503A and 503B pharmacy regulations as of 2023 enforcement updates, meaning licensed U.S. Compounding pharmacies cannot legally produce it for human use. Offshore peptide suppliers operate outside these rules entirely. You should understand this regulatory gap before purchasing.

Women are using TB-500 off-label for recovery, connective-tissue injury, hair thinning, and inflammatory conditions, and they deserve accurate reconstitution and storage guidance regardless.

Supplies You Need Before You Start

Getting the reconstitution right depends on having the correct materials assembled before you open the vial.

The Diluent: Bacteriostatic Water, Not Sterile Water

Bacteriostatic water for injection (BAC water) contains 0.9% benzyl alcohol as a preservative, which inhibits microbial growth and extends the usable life of your reconstituted peptide to approximately 28 days. Plain sterile water for injection contains no preservative; once you breach the stopper, contamination risk rises with every subsequent draw, and stability drops sharply, generally to 24-48 hours. Use BAC water.

Do not use bacteriostatic saline (0.9% NaCl with benzyl alcohol) as your primary diluent for TB-500. Salt solutions can accelerate peptide aggregation, particularly at higher concentrations.

Syringes and Needles

Two syringes serve different purposes here.

• Reconstitution syringe: A standard 3 mL or 5 mL luer-lock syringe with an 18-21 gauge needle to draw up BAC water and transfer it into the peptide vial without difficulty.
• Injection syringe: A 1 mL insulin syringe, 27-29 gauge, 0.5 inch needle. This is what you use to draw your dose and inject subcutaneously or intramuscularly. The fine gauge minimizes tissue trauma and is accurate to within 1-2 units (0.01-0.02 mL) at low volumes.

Alcohol Swabs and a Clean Surface

Standard 70% isopropyl alcohol swabs. Swab both stoppers (BAC water vial and peptide vial) and let them air-dry for 15-20 seconds before inserting any needle. Wet alcohol on a stopper can carry trace IPA into the solution.

Step-by-Step Reconstitution Protocol

This protocol follows aseptic technique principles consistent with USP General Chapter 797 sterile compounding standards, adapted for the home setting.

Step 1: Gather and Inspect

Inspect the lyophilized powder. It should be white to off-white, dry, and a cohesive cake or fine powder. Discard any vial with visible moisture, yellowing, or crumbling that looks degraded. Inspect the BAC water vial; it should be clear with no particulate.

Step 2: Calculate Your Target Concentration

This calculation determines how many units on the insulin syringe equal one dose. Pick a concentration before you add any liquid.

Formula:

Dose (mcg) ÷ Concentration (mcg/mL) × 1000 = Volume to draw (in mL) Then convert mL to insulin-syringe units: 1 mL = 100 units on a U-100 syringe.

Worked example for a 2 mg vial:

If you add 1 mL of BAC water to a 2 mg (2,000 mcg) vial, your concentration is 2,000 mcg/mL.

• A 500 mcg dose = 500 ÷ 2,000 = 0.25 mL = 25 units on the insulin syringe.
• A 250 mcg dose = 250 ÷ 2,000 = 0.125 mL = 12-13 units.

If you add 2 mL of BAC water to the same 2 mg vial, concentration drops to 1,000 mcg/mL and that same 500 mcg dose = 50 units. Larger volumes are easier to measure accurately with an insulin syringe.

Quick reference table for a 2 mg vial:

| BAC Water Added | Concentration | 250 mcg dose | 500 mcg dose | |---|---|---|---| | 1 mL | 2,000 mcg/mL | 12-13 units | 25 units | | 2 mL | 1,000 mcg/mL | 25 units | 50 units | | 4 mL | 500 mcg/mL | 50 units | 100 units |

For a 5 mg vial, multiply vial content by 2.5 and recalculate, or simply add 2.5 mL BAC water to get a clean 2,000 mcg/mL concentration matching the 2 mg/1 mL standard.

Step 3: Draw Up BAC Water

Swab the BAC water vial stopper. Insert your larger-gauge reconstitution syringe and withdraw the calculated volume of BAC water (e.g., 1-2 mL). Remove the needle cleanly.

Step 4: Add Diluent to the Peptide Vial

Swab the peptide vial stopper. Insert the needle at a 45-degree angle and aim it at the glass wall of the vial, not directly onto the powder cake. Allow the BAC water to run slowly down the inside wall. This prevents mechanical shear and foaming, both of which can degrade peptide structure by disrupting secondary folding.

Do not shake. Gently swirl or roll the vial between your palms for 30-60 seconds until the powder is fully dissolved. The solution should be clear and colorless to very pale yellow. Discard if cloudy, with visible particles, or if you see a white precipitate that does not dissolve with gentle agitation.

Step 5: Label and Date the Vial

Write the reconstitution date and the concentration on the vial with a marker. This is not optional. Without a label you cannot track the 28-day use window or the concentration you chose.

Storage After Reconstitution: What the Data Actually Shows

Lyophilized peptide stability and reconstituted peptide stability are completely different problems. Manufacturers can guarantee the dry powder at -20°C for 12-24 months, but once you add liquid, several degradation pathways begin.

Temperature

The 2-8°C refrigerator range is the evidence-based standard for short-peptide aqueous solutions preserved with benzyl alcohol. At room temperature (approximately 22-25°C), degradation accelerates roughly two-fold for every 10°C increase, consistent with the Arrhenius equation applied to peptide hydrolysis. A vial left on the counter for a weekend may lose a meaningful percentage of potency, especially in warm climates.

Store your reconstituted TB-500 in the back of the refrigerator, not in the door (temperature cycling from door opening accelerates degradation). Never freeze a reconstituted peptide; ice crystal formation disrupts the peptide's three-dimensional structure and can cause irreversible aggregation.

Light Exposure

Keep the vial in its original box or wrap it in foil. Photodegradation from UV light can cleave peptide bonds in aqueous solution, particularly the cysteine and methionine residues if present. TB-500's sequence does not contain methionine, but general light protection is still best practice.

The 28-Day Rule

The 28-day beyond-use date for multi-dose preserved preparations is codified in USP 797 for sterile preparations using preserved diluents. Benzyl alcohol at 0.9% provides effective antimicrobial protection within this window. Beyond 28 days, the preservative itself may begin to degrade, and cumulative peptide hydrolysis compounds the potency loss.

Discard at 28 days or at the first sign of cloudiness, whichever comes first.

Signs You Should Discard Immediately

• Visible cloudiness or white haze that does not clear with gentle warming
• Floating particles or flocculation
• Color change to brown or orange
• Smell of fermentation or any unusual odor on uncapping

Drawing and Injecting Your Dose

Subcutaneous Injection Technique

Most TB-500 protocols use subcutaneous (SubQ) injection into the lower abdomen, outer thigh, or flank. Rotate sites with each injection to prevent lipohypertrophy, the same rotation principle used in insulin injection guidelines.

1. Swab the stopper of your reconstituted vial. Allow to dry.
2. Draw slightly more than your target dose into the insulin syringe, then tap out any air bubbles and push back to the exact unit mark.
3. Pinch a 1-2 inch fold of subcutaneous fat between your thumb and forefinger.
4. Insert the needle at 45-90 degrees depending on your body fat depth. Thinner women should use 45 degrees with a 0.5-inch needle.
5. Inject slowly and steadily. Withdraw the needle and apply gentle pressure with a clean gauze square. Do not rub, as rubbing disperses the peptide away from the intended depot.

Intramuscular Injection

Some protocols call for intramuscular (IM) injection, typically into the vastus lateralis (outer thigh). IM injections may result in faster absorption but also more discomfort. For women, IM injection into the deltoid requires shorter needles given generally lower muscle mass; a standard 0.5-inch insulin-syringe needle may not reliably reach deltoid muscle in women with more subcutaneous tissue at that site. The outer thigh is the preferred IM site for self-injection in women.

Women-Specific Considerations Across Life Stages

Reproductive-Age Women (18-45)

Thymosin beta-4 is expressed endogenously in high concentrations in the uterus and ovaries and fluctuates with the menstrual cycle. Endogenous levels peak in the mid-luteal phase, corresponding to the window of implantation. Whether exogenous TB-500 administration interacts with this endogenous signaling cascade is unknown; no human menstrual-cycle pharmacokinetic data exists for synthetic TB-500. This is an honest evidence gap, not a reassurance.

Women with PCOS may have altered baseline thymosin beta-4 expression given their chronic low-grade inflammatory state, though direct data are absent. Women using hormonal contraception have different baseline inflammatory and tissue-repair profiles, and no studies have examined TB-500 pharmacokinetics in this context.

Perimenopause

Estrogen decline in perimenopause reduces collagen synthesis and slows tissue repair. Some women in this stage are drawn to peptides like TB-500 for musculoskeletal recovery. The theoretical rationale has biological plausibility given thymosin beta-4's role in fibroblast migration and collagen organization, but there are no randomized trials, no observational cohorts, and no safety data specific to perimenopausal women.

Postmenopausal Women

Bone resorption exceeds formation after menopause. Thymosin beta-4 has been shown in preclinical models to promote osteoblast activity, but translating mouse calvarial assay data to postmenopausal human bone metabolism is speculative. Anyone with osteoporosis should be working with an osteoporosis specialist and not relying on an unproven peptide as a primary intervention.

Pregnancy, Lactation, and Contraception

TB-500 is not safe to use during pregnancy. This is the unambiguous clinical position.

Thymosin beta-4 plays a documented role in embryonic cardiac development in animal models, with expression critical to formation of the epicardium and coronary vasculature. Exogenous administration at pharmacological doses during organogenesis could theoretically disrupt these endogenous developmental signals. No human pregnancy data exists. No animal teratogenicity studies have been conducted on the synthetic TB-500 fragment specifically, which means the data gap itself is a warning sign, not reassurance.

If you are trying to conceive, stop TB-500 before attempting pregnancy. The half-life of the peptide in plasma is short (likely under 30 minutes based on thymosin beta-4 pharmacokinetics in healthy adults), so tissue clearance occurs within days, but downstream effects on endometrial receptivity are unknown.

Lactation: Thymosin beta-4 is detectable in human breast milk at low physiological concentrations. Whether pharmacological doses of synthetic TB-500 administered subcutaneously would result in elevated breast milk concentrations is unknown. Given the lack of infant safety data and the fact that TB-500 is not approved for any human use, breastfeeding women should not use it.

Contraception requirement: TB-500 is not a recognized teratogen by FDA classification (it has no FDA classification, as it is not approved), but given the theoretical developmental risks described above, women of reproductive age using TB-500 should use reliable contraception throughout any course of use.

Who This May Be Appropriate For (and Who Should Avoid It)

This section does not constitute a prescription or a clinical recommendation. It reflects a framework for assessing personal fit given what the evidence does and does not show.

Women Who May Consider It (With Eyes Open)

• Women with documented musculoskeletal injuries who have exhausted conventional rehabilitation options and are working with a physician aware of their peptide use
• Healthy, non-pregnant, non-breastfeeding women who are not trying to conceive
• Women who understand the regulatory status and source their peptide from a third-party tested supplier with certificate of analysis

Women Who Should Avoid It

• Pregnant women, women trying to conceive, or breastfeeding women (see above)
• Women with active autoimmune conditions. Thymosin beta-4 modulates T-cell function and could theoretically alter disease activity in conditions like lupus, rheumatoid arthritis, or Hashimoto's thyroiditis. No clinical data guides this risk.
• Women with a personal or family history of hormone-sensitive cancers. Thymosin beta-4 has been identified as a pro-angiogenic factor in certain tumor microenvironments; this is mechanistically concerning even without direct evidence of tumor promotion.
• Women who are immunocompromised, on chemotherapy, or have active infections

Common Dosing Protocols (What Is Reported; Not a Prescription)

No FDA-approved dosing protocol exists. The following reflects what circulates in published peptide-use surveys and compounding literature, presented for harm reduction purposes only.

Reported ranges in off-label use:

• Loading phase: 500 mcg to 2,000 mcg, two to three times per week, for 4-6 weeks
• Maintenance phase: 200 mcg to 500 mcg once or twice per week

Women in off-label user surveys generally report using doses at the lower end of these ranges. Body weight and lean mass do influence distribution volume for subcutaneous peptides, and women on average have approximately 10% higher body fat than men at equivalent BMI, which affects the subcutaneous depot and absorption kinetics in a way that is not yet quantified for TB-500 specifically.

No dose-ranging trial in women exists. Extrapolating male-default clinical experience to women is the kind of evidence gap that historically affected drug development for decades. You should know this before you dose.

Frequently Asked Questions